Online citations, reference lists, and bibliographies.
← Back to Search

Evaluation Of New Biomarkers In The Prediction Of Malignant Mesothelioma In Subjects With Environmental Asbestos Exposure

Melike Demir, H. Kaya, Mahşuk Taylan, A. Ekinci, Sureyya Yılmaz, F. Teke, C. Sezgi, A. C. Tanrıkulu, Fatih Meteroğlu, A. Şenyiğit
Published 2016 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
IntroductionThe purpose of this study was to investigate the potential value of certain biomarkers in predicting the presence of malignant pleural mesothelioma (MPM) in individuals environmentally exposed to asbestos.MethodsThis prospective study investigated three groups; a control group composed of 41 healthy subjects, an asbestos exposure group consisting of 48 individuals, and a MPM group consisting of 42 patients. Serum levels of soluble mesothelin-related peptide (SMRP), thioredoxin-1 (TRX), epidermal growth factor receptor (EGFR), fibulin-3, syndecan-1 (SDC-1), and mesothelin were determined.ResultsBenign pleural plaques were present in 27 (58.3 %) of the individuals in the asbestos exposure group. The asbestos exposure group had significantly higher mean TRX, SMRP, and mesothelin levels compared to the control group (p = 0.023, p = 0.011, and p < 0.001, respectively). Compared to the asbestos exposure group, the MPM group had significantly higher mean EGFR, TRX, SMRP, and fibulin-3 levels (p = 0.041, p = 0.023, p = 0.002, and p = 0.001, respectively), and significantly lower mean SDC-1 levels (p = 0.002). Unlike the other biomarkers, SMRP and TRX levels increased in a graded fashion among the control, asbestos exposure, and MPM groups, respectively. Area under the curve values for SMRP and TRX were 0.86 and 0.72, respectively (95 % CI 0.79–0.92 and p < 0.001 for SMRP, and 95 % CI 0.62–0.81 and p < 0.001 for TRX). The cut-off value for SMRP was 0.62 nmol/l (sensitivity: 97.6 %, specificity: 68.9 %, positive predictive value (PPV): 56.2 %, and negative predictive value (NPV): 98.3 %) and for TRX was 156.67 ng/ml (sensitivity: 92.9 %, specificity: 77.6 %, PPV: 41.4 %, and NPV: 92.1 %). The combination of the biomarkers reached a sensitivity of 100 %, but had lower specificity (as high as 27.7 %).ConclusionsSerum biomarkers may be helpful for early diagnosis of MPM in asbestos-exposed cases. SMRP and TRX increased in a graded fashion from the controls to asbestos exposure and MPM groups. These two seem to be the most valuable biomarkers for the diagnosis of MPM, both individually and in combination.
This paper references
Specific Syndecan-1 Domains Regulate Mesenchymal Tumor Cell Adhesion, Motility and Migration
F. Zong (2011)
Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers
J. Trupiano (2004)
Chromosome analysis in pleural effusions. Efficiency of this method in the differential diagnosis of pleural effusions.
M. Metintas (1994)
The paradoxical role of thioredoxin on oxidative stress and aging.
Geneva M. Cunningham (2015)
Serum Biomarkers in Patients with Mesothelioma and Pleural Plaques and Healthy Subjects Exposed to Naturally Occurring Asbestos
Mehmet Bayram (2013)
Combined Serum Mesothelin and Plasma Osteopontin Measurements in Malignant Pleural Mesothelioma
A. Cristaudo (2011)
Asbestos causes DNA strand breaks in cultured pulmonary epithelial cells: role of iron-catalyzed free radicals.
D. Kamp (1995)
The Role of Syndecan-1 in Cellular Signaling and its Effects on Heparan Sulfate Biosynthesis in Mesenchymal Tumors
T. Szatmári (2013)
Molecular cloning of syndecan, an integral membrane proteoglycan
S. Saunders (1989)
Low Frequency of EGFR Mutations in Pleural Mesothelioma Patients, Cologne, Germany.
V. Schildgen (2014)
Chromosome Analysis in Pleural Effusions
M. Metintas (1994)
Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma
V. Kovač (2015)
Diagnostic and Prognostic Value of Soluble Syndecan-1 in Pleural Malignancies
Filip Mundt (2014)
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
Kevin Hollevoet (2012)
Molecular tumor markers for asbestos‐related mesothelioma: Serum diagnostic markers
M. Maeda (2006)
Epidermal growth factor receptor dependence in human tumors: more than just expression?
C. Arteaga (2002)
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
F. Ciardiello (2001)
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
H. Pass (2012)
Syndecan-1 expression in different soft tissue tumours.
Z. Orosz (2001)
Focus on molecules: fibulin-3 (EFEMP1).
Y. Zhang (2010)
Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma.
L. Santarelli (2015)
Oxidative Status and Acute Phase Reactants in Patients with Environmental Asbestos Exposure and Mesothelioma
C. Sezgi (2014)
Syndecan‐1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome
S. Kumar-Singh (1998)
Soluble mesothelin-related protein--a blood test for mesothelioma.
B. Robinson (2005)
Asbestos modulates thioredoxin-thioredoxin interacting protein interaction to regulate inflammasome activation
Joyce K. Thompson (2014)
Fibulin-3 as a diagnostic biomarker in patients with malignant mesothelioma.
H. Kaya (2015)
Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma.
R. Gaafar (2010)
Serum Levels of Soluble Mesothelin-Related Peptides in Malignant and Nonmalignant Asbestos-Related Pleural Disease: Relation with Past Asbestos Exposure
J. R. Portal (2009)
Clinical Significance Of Pleural Effusion Mesothelin In Malignant Pleural Mesothelioma
S. Yamada (2012)
Fibulins: physiological and disease perspectives
W. Argraves (2003)
Properties and biological activities of thioredoxins.
G. Powis (2001)
Malignant Mesothelioma and Occupational Exposure to Asbestos: A Clinicopathological Correlation of 1445 Cases
V. Roggli (2002)
Epidemiology of pleural mesothelioma in a population with non‐occupational asbestos exposure
M. Metintas (2008)
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
A. Scherpereel (2006)
Serum Thioredoxin-1 as a Diagnostic Marker for Malignant Peritoneal Mesothelioma
C. Tabata (2013)
Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
Ai Cui (2014)
Evaluation of Soluble Mesothelin-related Peptide as a Diagnostic Marker of Malignant Pleural Mesothelioma Effusions: Its Contribution to Cytology
P. Canessa (2013)
Colon cancer at the molecular level--usefulness of epithelial-mesenchymal transition analysis.
Ana-Maria Todosi (2012)
Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population
Eun-Kee Park (2010)
Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer
T. Mitsudomi (2010)
Asbestos exposure affects poly(ADP-ribose) polymerase-1 activity: role in asbestos-induced carcinogenesis.
M. Tomasetti (2011)
Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma.
K. Fukuoka (2013)
Increased 8-isoprostane, a marker of oxidative stress in exhaled breath condensate in subjects with asbestos exposure.
D. Pelclova (2008)

This paper is referenced by
Identification of Malignant Mesothelioma Risk Factors through Association Rule Mining
Talha Mahboob Alam (2019)
Chapter 12 Biomarkers of Response to Asbestos Exposure
Blair ()
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.
I. Opitz (2020)
Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis
Dongxu Pei (2017)
Fibulin-3 as biomarker of malignant mesothelioma.
C. Ledda (2019)
Asbestos Air Pollution: Description of a Mesothelioma Cluster Due to Residential Exposure from an Asbestos Cement Factory
L. Vimercati (2020)
Breath Analysis: A Systematic Review of Volatile Organic Compounds (VOCs) in Diagnostic and Therapeutic Management of Pleural Mesothelioma
A. Catino (2019)
Malignant Mesothelioma: Time to Translate?
A. Napolitano (2016)
Mild steel welding is associated with alterations in circulating levels of cancer-related proteins
A. Gliga (2019)
Diagnosis and prognosis-review of biomarkers for mesothelioma.
H. H. Sun (2017)
Biomarkers for malignant pleural mesothelioma: a meta-analysis.
Christina Gillezeau (2019)
Prediction of pneumoconiosis by serum and urinary biomarkers in workers exposed to asbestos-contaminated minerals
H. Yang (2019)
Follow-up of Soluble Mesothelin-Related Protein Levels in Participants With Asbestos-Related Disorders
E. Park (2020)
Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation
L. Ferrari (2020)
Sulfatase-1 knockdown promotes in vitro and in vivo aggressive behavior of murine hepatocarcinoma Hca-P cells through up-regulation of mesothelin
S. Mahmoud (2017)
Asbestos Exposures, Mesothelioma Incidence and Mortality, and Awareness by General Practitioners in the Molise Region, Central Italy
G. Ripabelli (2018)
Breath analysis as a diagnostic and screening tool for malignant pleural mesothelioma: a systematic review.
Lisa Brusselmans (2018)
Diagnostic value of fibulin-3 for malignant pleural mesothelioma: A systematic review and meta-analysis
Ran Ren (2016)
Biomarkers of Response to Asbestos Exposure
C. Mesaros (2017)
Calretinin as a blood-based biomarker for mesothelioma
G. Johnen (2017)
Risk Factors Identification of Malignant Mesothelioma: A Data Mining Based Approach
Muhammad Latif (2020)
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
A. Scherpereel (2020)
Epidemiology of Environmental Exposure and Malignant Mesothelioma.
Bian Liu (2017)
Semantic Scholar Logo Some data provided by SemanticScholar